Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Services business in Healthcare — Hospitals & Diagnostics.”
₹2,461 Cr service revenue.
Employee costs at 19.6% of revenue — primary cost driver.
“year on year growth of 10.”
“We are confident that we should be able to deliver between 11% to 12% organic growth for the year.”
“INR $6.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 22.1%▲ | 7.9% |
| ROCE | 27.1%▲ | 11.3% |
| Net Margin | 19.1%▲ | 9.3% |
| EBITDA Margin | 30.3%▲ | 21.9% |
| Debt To Equity | 0.00x▼ | 0.16x |
| Rev Growth 3yr | 6.1%▼ | 12.4% |
| EPS Growth 3yr | 12.1%▲ | 11.8% |
| Employee Cost Ratio | 19.60x | - |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2,663 Cr +8.2% | ₹2,461 Cr +10.5% | ₹2,227 Cr +10.4% | ₹2,017 Cr -3.4% | ₹2,087 Cr +32.0% | ₹1,581 Cr +18.9% | ₹1,330 Cr +10.6% | ₹1,203 Cr |
| Other Income | ₹103 Cr +10.4% | ₹93 Cr +35.0% | ₹69 Cr +65.9% | ₹42 Cr -20.6% | ₹53 Cr +2.3% | ₹51 Cr -6.7% | ₹55 Cr +19.6% | ₹46 Cr |
| Total Income | ₹2,766 Cr +8.3% | ₹2,555 Cr +11.3% | ₹2,296 Cr +11.5% | ₹2,059 Cr -3.8% | ₹2,140 Cr +31.1% | ₹1,633 Cr +17.8% | ₹1,385 Cr +10.9% | ₹1,249 Cr |
| COGS | ₹517 Cr +7.4% | ₹482 Cr +6.7% | ₹451 Cr +0.9% | ₹447 Cr -11.0% | ₹502 Cr +26.4% | ₹397 Cr +33.0% | ₹299 Cr +13.8% | ₹262 Cr |
| ₹2,073 Cr +7.4% | ₹1,930 Cr +7.8% | ₹1,790 Cr +4.4% | ₹1,715 Cr +3.0% | ₹1,665 Cr +34.5% | ₹1,238 Cr +15.2% | ₹1,075 Cr +13.3% | ₹949 Cr | |
| Profit Before Tax | ₹662 Cr +6.0% | ₹625 Cr +23.6% | ₹506 Cr +47.0% | ₹344 Cr -27.6% | ₹475 Cr +20.4% | ₹394 Cr +27.0% | ₹311 Cr +3.3% | ₹301 Cr |
| Exceptional Items | (₹30 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| ₹129 Cr -2.4% | ₹133 Cr -7.5% | ₹143 Cr +39.3% | ₹103 Cr -17.5% | ₹125 Cr +27.3% | ₹98 Cr +18.1% | ₹83 Cr -17.2% | ₹100 Cr | |
| Net Profit | ₹533 Cr +8.3% | ₹492 Cr +35.9% | ₹362 Cr +50.3% | ₹241 Cr -31.2% | ₹350 Cr +18.1% | ₹297 Cr +30.3% | ₹228 Cr +13.5% | ₹201 Cr |
| Profit (Owners) | ₹528 Cr +8.5% | ₹487 Cr +36.2% | ₹358 Cr +49.7% | ₹239 Cr -30.7% | ₹345 Cr +18.2% | ₹292 Cr +29.1% | ₹226 Cr +13.4% | ₹199 Cr |
| Minority Interest | ₹5 Cr -5.9% | ₹5 Cr +10.9% | ₹5 Cr +109.1% | ₹2 Cr -60.0% | ₹6 Cr +12.2% | ₹5 Cr +188.2% | ₹2 Cr +30.8% | ₹1 Cr |
| Other Comprehensive Income | (₹2 Cr) +52.8% | (₹4 Cr) -500.0% | (₹0.60 Cr) ↓ Decline | ₹2 Cr ↑ Recovery | (₹1 Cr) -62.5% | (₹0.80 Cr) +27.3% | (₹1 Cr) +45.0% | (₹2 Cr) |
| EPS | ₹31.55 | ₹29.14 | ₹21.42 | ₹14.33 | ₹20.69 | ₹17.49 | ₹13.55 | ₹11.95 |
| Diluted Shares | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Dr. Lal Path Labs Ltd. has informed the Exchange about Copy of Newspaper Publication
Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation
Dr. Lal Path Labs Ltd. has informed the Exchange regarding a press release dated April 30, 2026, titled "Press Release on Audited Financial Results (Standalone and Consolidated) for the Quarter and Fi...
Dr. Lal Path Labs Ltd. has informed the Exchange about re-appointment of Auditor(s):1. M/s Ernst & Young LLP (EY) as the Internal Auditors of the Company for the Financial Year 2026-27.2. M/s A.G. Aga...
Dr. Lal Path Labs Ltd. has informed the Exchange about Senior Management Personnel
Dr. Lal Path Labs Ltd. has informed the Exchange about acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited ( SDCPL ) from its existing Shareholders. Post acquisition, SDCPL shal...
Dr. Lal Path Labs Ltd. has informed the Exchange about the incorporation of a Wholly Owned Subsidiary Company
Dr. Lal Path Labs Ltd. has informed the Exchange about Convening of 32nd Annual General Meeting (AGM) of the Company on Saturday, July 25, 2026, through Video Conferencing/ Other Audio-Visual Means (V...
Dr. Lal Path Labs Ltd. has informed the Exchange regarding Appointment of Mr Rajit Mehta as Non- Executive Independent Director of the company w.e.f. July 27, 2026.
Dr. Lal Path Labs Ltd. has informed the Exchange regarding Allotment of 82750 Shares.
Dr. Lal Path Labs Ltd. has informed the Exchange that Record date for the purpose of Dividend is 26-Jun-2026.
Dr. Lal Path Labs Ltd. has informed the Exchange regarding Outcome of Board Meeting held on April 30, 2026.
Dr. Lal Path Labs Ltd. has informed the Exchange that Board of Directors at its meeting held on April 30, 2026, recommended Final Dividend of Rs. 4 per equity share.
Dr. Lal Path Labs Ltd. has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Dr. Lal Path Labs Ltd. has informed the Exchange about Schedule of meet